NASDAQ NMS - GLOBAL MARKET · IRD
-1.95% · -$0.0800 · Vol 869.0K
Market closed · last close 4:00 PM ET · price as of 16:01:38 ET
Opus Genetics Inc

Opus Genetics Inc

Biotechnology
$4.02
+ Add to watchlist
Card

Veridion Score

Refresh
Score snapshot refresh in progress
Veridion Score History · 90D

Composite trend over time

HISTORY REFRESH IN PROGRESS
REFRESHES DAILY
AI Analysis
Sovereign

Why is IRD moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Catalyst calendar
Dated receipts for IRD are being assembled.
About Opus Genetics Inc
PHARMACEUTICAL PREPARATIONS
Listed since
2020
Employees
28
Country
US

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.12
Day high
$4.23
Day low
$3.94
Previous close
$4.10
52W high
$4.35
-7.59% from high
52W low
$3.78
42% of range
Market cap
$338.5M
EPS
$-1.4500
Shares out
82.6M
Volume
869K
VWAP
$4.03
Price history computed in-house
1W
-7.59%
1M
+2.94%
SMA 50 $4.04 · below
SMA 200 $4.04 · below
52W position 42%
Veridion warehouse edge

Warehouse intelligence for IRD.

Veridion Score
22
0: 131: 402: 363: 104: 815: 60
Congress 30d
0
No recent disclosure on file.
Insider activity
See Form 4 panel below.
13F holders
None on file
Capital Web snapshots checked.
Disclosure-sourced lobbying and contract detail remains attributed in the full panels below.
Data ledger
Quote and day range
Refresh interval: 30 seconds
Source: Market data
Veridion Score
Coverage building
Source: Veridion methodology
Chart and risk context
Daily bars with no missing-bar fill
Source: Market data
News and filings
Refresh intervals shown inside each panel
Source: Market news and federal filings
Financials
Statements refresh in progress
SEC Form 4 ledger

IRD insider activity

Opus Genetics Inc

Score
Coverage building
Pressure
Net selling
Filings
22
Buys / sells
4 / 18
Net value
-$15.2M
Insiders
9
Named filers
FF
Foundation Fighting Blindness Retinal Degeneration Fund
Insider
Leadership
ZA
Zaremba Rabourn Amy
Insider
Leadership
MG
Magrath George
Insider
Leadership
Cluster

No multi-insider buying cluster in the last 90 days

Net pressure

Net selling: -$15.2M across loaded Form 4 rows.

Convergence not established

Loaded official disclosures do not show all three sources aligned on this ticker.

Filing dateTrade dateInsiderTitleTypePriceQtyOwnedValueReceipt
2026-05-202026-05-18Foundation Fighting Blindness Retinal Degeneration FundInsidersell$4.351,700,0003,792,171$7.4MSEC Form 4
2026-04-272026-04-23Zaremba Rabourn AmyInsidersell$5.201,641188,671$9KSEC Form 4
2026-04-272026-04-23Magrath GeorgeInsidersell$5.229,5111,741,344$50KSEC Form 4
2026-04-272026-04-23Jayagopal AshwathInsidersell$5.197,542509,233$39KSEC Form 4
2026-04-272026-04-23Gagnon Robert E.Insidersell$5.187,842592,158$41KSEC Form 4
Full Form 4 history requires Sovereign

Showing 5 recent rows. Sovereign unlocks 17 additional rows, full sorting, and the named-filer history.

Upgrade to Sovereign · $25/mo
Source: SEC EDGAR Form 4. Rows with missing price or quantity are excluded rather than zero-filled.Methodology
Congress · 90D
Congress filing snapshot refresh in progress
Federal contracts

IRD contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IRD in this window.
Lobbying spend

IRD lobbying filings, year to date.

Registered lobbying filings matched to Opus Genetics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IRD in this window.
Latest news · IRD
Refresh interval: 5 minutes · Source: Market news insights
News snapshot refresh in progress
Analyst ratings
Sovereign unlock shows live analyst consensus for IRD.
Options
Sovereign unlock shows live options positioning for IRD.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.